Furthermore, we provided some observations about the NRP-1 contribution to the cisplatin sensitivity in HNSCC tumors both in in vitro experiments and in the clinical setting; the latter deserves further investigations, such as in a clinical trial. The gene discussed is NRP1; the disease is head and neck squamous cell carcinoma.